Rimonabant (Acomplia, Zimulti) is an anti-obesity diet pill and has the potential as a smoking cessation drug. It offers solution to improve a variety of cardiometabolic risk factors in obese and overweight people. These risk factors include high LDL cholesterol levels, hypertension and diabetes and other factors being investigated as insulin resistance, low HDL cholesterol, and high triglyceride levels. Rimonabant comes in the form of 20mg pill to be taken daily.

Rimonabant acts by blocking the CB1 receptors are found in the brain and in the peripheral organs and are part of the endocannabinoid system which is believed to play an important role in regulating body weight and controlling energy balance. Rimonabant blocks CB1 receptors and thus decreases the hyperactivity of the endocannabinoids system resulting in less intake of food which in turn leads to weight loss.(buy rimonabant pill) 

Based on the data available from various clinical trials, Rimonabant (Acomplia, Zimulti,buy rimonabant pills) is an extremely safe medication with minor side effects such as nausea, mood swings, anxiety and dizziness.Rimonabant is recommended to be taken along with regular exercise and a diet regime for optimum results. Patients with a Body Mass Index (BMI) greater than or equal to 30kg/m2 can benefit from taking a daily pill of Rimonabant of 20mg along with proper exercise and diet.Various trials conducted have shown remarkable results making Rimonabant (Acomplia, Zimulti) one of the most sought after anti-obesity medications worldwide.

Rimonabant is also known as wonder drug as it treats obesity and smoking cessation simultaneously.Rimonabant (brand name Acomplia,buy rimonabant pill) is an anorectic anti-obesity drug. It is a CB1 cannabinoid receptor antagonist. Its main avenue of effect is reduction in appetite. Rimonabant is currently being sold in the United Kingdom by Sanofi-Aventis and in Denmark by Sanofi-Synthelabo under the trade name Acomplia. It is believed, although not confirmed, that if the drug is approved in the United States, it will be sold under the trade name Zimulti.(buy rimonabant pill)

Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. In Europe, it is indicated for use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m2, or patients wih a BMI greater than 27 kg/m2 with associated risk factors, such as type 2 diabetes or dyslipidaemia. In the UK it has been available since the end of July, 2006.Rimonabant may also be found to be effective in assisting some smokers to quit smoking. Sanofi-Aventis is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy.